Clinical trials for BET inhibitors run ahead of the science.
暂无分享,去创建一个
[1] A. Belkina,et al. The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis , 2014, Journal of leukocyte biology.
[2] Qiang Zhang,et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. , 2014, Cancer cell.
[3] J. Deeney,et al. Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. , 2013, Vitamins and hormones.
[4] J. Fletcher,et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. , 2003, Cancer research.
[5] James E. Bradner,et al. Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.
[6] Ming-Ming Zhou,et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. , 2005, Journal of the American Chemical Society.
[7] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[8] P. Sebastiani,et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV‐1 , 2012, Journal of leukocyte biology.
[9] Julio E. Agno,et al. Small-Molecule Inhibition of BRDT for Male Contraception , 2012, Cell.
[10] Shwu‐Yuan Wu,et al. Brd4 links chromatin targeting to HPV transcriptional silencing. , 2006, Genes & development.
[11] Thomas L. Rothstein,et al. Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia , 2004 .
[12] L. Cascione,et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.
[13] T. Mahmoudi,et al. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription , 2007, Proceedings of the National Academy of Sciences.
[14] R. Weissleder,et al. Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells , 2014, eLife.
[15] F. Westermann,et al. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition , 2015, Clinical Cancer Research.
[16] David H Perlman,et al. Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. , 2009, The American journal of pathology.
[17] P. Howley,et al. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Interacts with Bromodomain Protein Brd4 on Host Mitotic Chromosomes , 2006, Journal of Virology.
[18] Jessica E. Bolden,et al. Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition , 2014, Cell reports.
[19] D. Faller,et al. Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. , 2006, Journal of proteome research.
[20] I B Dawid,et al. The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins. , 1992, Nucleic acids research.
[21] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[22] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[23] R. Hardison,et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes , 2011, Proceedings of the National Academy of Sciences of the United States of America.
[24] Asher Mullard. Use of personalized cancer drugs runs ahead of the science , 2015, Nature.
[25] T. Schulz,et al. Brd2/RING3 Interacts with a Chromatin-Binding Domain in the Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 (LANA-1) That Is Required for Multiple Functions of LANA-1 , 2005, Journal of Virology.
[26] G. Denis. Duality in bromodomain-containing protein complexes. , 2001, Frontiers in bioscience : a journal and virtual library.
[27] T. Schulz,et al. Latent Nuclear Antigen of Kaposi’s Sarcoma-Associated Herpesvirus Interacts with RING3, a Homolog of theDrosophila Female Sterile Homeotic (fsh) Gene , 1999, Journal of Virology.
[28] M. Zwahlen,et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.
[29] N. LeBrasseur,et al. Brd2 disruption in mice causes severe obesity without Type 2 diabetes. , 2009, The Biochemical journal.
[30] Łukasz M. Boryń,et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.
[31] Shwu‐Yuan Wu,et al. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. , 2013, Molecular cell.
[32] D. Faller,et al. Tumor-specific and Proliferation-specific Gene Expression Typifies Murine Transgenic B Cell Lymphomagenesis* , 2007, Journal of Biological Chemistry.
[33] Lei Zeng,et al. Structure and ligand of a histone acetyltransferase bromodomain , 1999, Nature.
[34] A. Belkina,et al. BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses , 2013, The Journal of Immunology.
[35] C. Rice,et al. Suppression of inflammation by a synthetic histone mimic , 2010, Nature.
[36] R. Kornberg,et al. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] Declan Butler,et al. Scientists in the dark after French clinical trial proves fatal , 2016, Nature.
[38] I. Dawid,et al. The trithorax gene, a trans-acting regulator of the bithorax complex in Drosophila, encodes a protein with zinc-binding domains. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[39] Thomas B. Kepler,et al. Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNFα production , 2015, Obesity.
[40] A. Salmeron,et al. BET bromodomain inhibition suppresses TH17-mediated pathology , 2013, The Journal of experimental medicine.
[41] Jennifer A. Smith,et al. The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3 , 2011, Molecular and Cellular Biology.
[42] S. Knapp,et al. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins. , 2016, Journal of medicinal chemistry.
[43] M. Green,et al. A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator. , 1996, Genes & development.
[44] A. Belkina,et al. BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.
[45] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[46] Jerard Hurwitz,et al. A Mammalian Bromodomain Protein, Brd4, Interacts with Replication Factor C and Inhibits Progression to S Phase , 2002, Molecular and Cellular Biology.
[47] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.